(Q35215084)

7 August 2017

1 reference

title

Biochemical recurrence of prostate cancer (English)

1 reference

7 August 2017

1 reference

Judd W Moul

1

1 reference

7 August 2017

publication date

1 September 2003

1 reference

Current Problems in Cancer

7 August 2017

published in

1 reference

7 August 2017

volume

27

1 reference

7 August 2017

issue

5

1 reference

7 August 2017

page(s)

243-272

1 reference

7 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Treatment options after failure of local curative treatments in prostate cancer: a controversial issue

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

A catalog of prostate cancer nomograms

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Management of prostate cancer after prostatectomy: treating the patient, not the PSA

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Indium-111 Capromab Pendetide (ProstaScint) Images Before and After Salvage Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Evaluation and management of the man who has failed primary curative therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Positron emission tomography in urological oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Effect of Adjuvant Radiation Therapy on Prostate Specific Antigen Following Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Serum prostate-specific antigen after post-prostatectomy radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Radical prostatectomy after radiotherapy for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Salvage radical prostatectomy for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Salvage Radical Prostatectomy for Radiorecurrent Adenocarcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Radical prostatectomy after definitive radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

The role of radical surgery in the management of radiation recurrent and large volume prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Salvage surgery for radiation failure in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Salvage radical prostatectomy after radiation therapy and brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Salvage radical prostatectomy in the management of locally recurrent prostate cancer after 125I implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Introduction. Recent scientific and technological advances have challenged the traditional treatment options for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Cryosurgery for prostate cancer: new technology and indications

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Salvage brachytherapy for localized prostate cancer after radiotherapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

The management of PSA failure after radical radiotherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Estrogens in the Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Combined androgen blockade in prostate cancer: meta-analyses and associated issues

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Treatment with finasteride following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Combined finasteride and flutamide therapy in men with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the dunning rat prostatic carcinoma, R-3327

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

The bicalutamide Early Prostate Cancer Program. Demography

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

A review of studies of hormonal adjuvant therapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Sequential androgen blockade: a biological study in the inhibition of prostatic growth

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2803%2900032-1

7 January 2021

10.1016/S0147-0272(03)00032-1

Identifiers

DOI

1 reference

release_ak3hthzgyvcbnc4vls6xlf4ojq

7 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ak3hthzgyvcbnc4vls6xlf4ojq

24 November 2022

mapped directly with Wikidata item

1 reference